Strategies for Preventing Group B Streptococcal Disease
First isolated in 1887, Streptococcus agalactiae (Lancefield Group B streptococcus; GBS) was reported as a human pathogen in the late 1930s following its isolation from vaginal cultures. It was not until the 1970s, however, that GBS emerged as the leading cause of sepsis in the neonatal period.
KeywordsConjugate Vaccine Neonatal Sepsis Streptococcus Agalactiae Early Onset Disease Late Onset Disease
Unable to display preview. Download preview PDF.
- Centers for Disease Control and Prevention (1996). Prevention of perinatal group B streptococcal disease: A public health perspective. MMWR 45(RR-7), 1–24.Google Scholar
- Nicoll, A. and Heath, P.T. (2000). Group B streptococcal infection. Commentary. Arch. Dis. Child. Fetal. Neonatal. Ed. 82(3), F207.Google Scholar
- Royal College of Obstetricians and Gynaecologists (2003). Clinical Greentop Guidelines. Prevention of Early Onset Neonatal Group B Streptococcal Disease, (www.rcog.org.uk)
- Smaill, F. (1999). Intrapartum antibiotics for group B streptococcal colonisation. Cochrane Database Syst. Rev. 2, CD000115.Google Scholar